Brazil is an upper-middle income
developing country as classified by World Bank. Brazil has 200 million people,
most whom live in poverty with a total life expectancy of 72.9 years. Many
people suffer from chronic diseases such as cardiovascular diseases, chronic
respiratory diseases, cancer, and diabetes. These diseases accounted for 72% of
the disease burden for the poor in Brazil in 2007, with neuropsychiatric
disorders being the leading cause of death.
Partnership with the private sector has emerged as a new path for development in biotechnology, partially due to resource and management limitations in the public sector. Neither the public nor the private sector alone can operate optimally in the health care system, and partnerships are crucial for bringing resources to public health to benefit the poor. Such partnerships diminish the traditional distinction between the public and private sectors' aims and responsibilities
Health biotechnology is the fastest
growing arena in which developing countries can address their specific health
problems. It has the potential to bring economic benefits to the country. For
most developing countries, improvements to the health status of the poor and to
health care accessibility are a critical challenge. To overcome this challenge,
developing countries must place science, technology, and innovation at the centre
of their development strategies.
The private sector might be the key
to the development of health biotechnology.
Sem comentários:
Enviar um comentário